CI
RIGL icon

Cowen Inc’s Rigel Pharmaceuticals RIGL Stock Holding History

Cowen Inc’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-15,000
Closed – – 432
2014
Q4 		$0 Sell
15,000
-3,500
-19% -$70.8K ﹤0.01% 285
2014
Q3 		$359K Buy
18,500
+10,000
+118% +$282K 0.04% 210
2014
Q2 		$309K Buy
8,500
+3,000
+55% +$102K 0.03% 198
2014
Q1 		$213K Buy
+5,500
New +$196K 0.03% 172

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cowen Inc's RIGL Position: Q1 2015 in Review

Cowen Inc sold out of Rigel Pharmaceuticals (RIGL) in Q1 2015, closing a stake of 15,000 shares.

Cowen Inc first reported a position in RIGL in Q1 2014 and held it in 4 quarters. The position peaked at $359K in Q3 2014. 113 funds tracked by Wall St. Rank hold RIGL as of Q1 2015.

  • Cowen Inc reported no remaining Rigel Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Cowen Inc sold 15,000 Rigel Pharmaceuticals shares in Q1 2015.
  • Cowen Inc first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 4 quarters.
  • Cowen Inc's Rigel Pharmaceuticals position peaked at $359K in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2015.

Based on Cowen Inc's 13F filing for Q1 2015, filed 18 May 2015.